Open AccessS754 Risankizumab as Induction Therapy in Patients with Moderately to Severely Active Crohn’s Disease Who Failed 1 vs >1 Prior Biologic Treatment: Results From the MOTIVATE Study
Author(s) -
Remo Panaccione,
Stefan Schreiber,
Laurent PeyrinBiroulet,
Edward V. Loftus,
Marla Dubinsky,
Marc Ferrante,
Alexandra Song,
Bidan Huang,
Xiaomei Liao,
Sofie Berg,
W. Rachel Duan,
Kori Wallace,
Brian G. Feagan
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000776548.94565.6c
Subject(s) - medicine , ustekinumab , crohn's disease , clinical endpoint , gastroenterology , placebo , randomization , population , randomized controlled trial , intention to treat analysis , inflammatory bowel disease , disease , infliximab , pathology , alternative medicine , environmental health